Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance.

Hatanpaa KJ, Burma S, Zhao D, Habib AA.

Neoplasia. 2010 Sep;12(9):675-84. Review.

2.

Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells.

Ramnarain DB, Park S, Lee DY, Hatanpaa KJ, Scoggin SO, Otu H, Libermann TA, Raisanen JM, Ashfaq R, Wong ET, Wu J, Elliott R, Habib AA.

Cancer Res. 2006 Jan 15;66(2):867-74.

3.
4.

Epidermal growth factor receptor variant III renders glioma cancer cells less differentiated by JAGGED1.

Kim EJ, Kim SO, Jin X, Ham SW, Kim J, Park JB, Lee JY, Kim SC, Kim H.

Tumour Biol. 2015 Apr;36(4):2921-8. doi: 10.1007/s13277-014-2922-9. Epub 2014 Dec 17.

PMID:
25514871
5.

The EGFRvIII variant in glioblastoma multiforme.

Gan HK, Kaye AH, Luwor RB.

J Clin Neurosci. 2009 Jun;16(6):748-54. doi: 10.1016/j.jocn.2008.12.005. Epub 2009 Mar 25. Review.

PMID:
19324552
6.

Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomas.

Nicholas MK, Lukas RV, Jafri NF, Faoro L, Salgia R.

Clin Cancer Res. 2006 Dec 15;12(24):7261-70. Review.

7.

Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene.

Johns TG, Stockert E, Ritter G, Jungbluth AA, Huang HJ, Cavenee WK, Smyth FE, Hall CM, Watson N, Nice EC, Gullick WJ, Old LJ, Burgess AW, Scott AM.

Int J Cancer. 2002 Mar 20;98(3):398-408.

8.

Aberrant receptor signaling in human malignant gliomas: mechanisms and therapeutic implications.

Nagane M, Lin H, Cavenee WK, Huang HJ.

Cancer Lett. 2001 Jan;162 Suppl:S17-S21. Review.

PMID:
11164186
9.

Molecular pathologic diagnosis of epidermal growth factor receptor.

Maire CL, Ligon KL.

Neuro Oncol. 2014 Oct;16 Suppl 8:viii1-6. doi: 10.1093/neuonc/nou294. Review.

10.
11.
12.

The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered.

Gan HK, Cvrljevic AN, Johns TG.

FEBS J. 2013 Nov;280(21):5350-70. doi: 10.1111/febs.12393. Epub 2013 Jul 8. Review.

13.

Epidermal growth factor receptor variant III-induced glioma invasion is mediated through myristoylated alanine-rich protein kinase C substrate overexpression.

Micallef J, Taccone M, Mukherjee J, Croul S, Busby J, Moran MF, Guha A.

Cancer Res. 2009 Oct 1;69(19):7548-56. doi: 10.1158/0008-5472.CAN-08-4783. Epub 2009 Sep 22.

14.

Inhibition of the type III epidermal growth factor receptor variant mutant receptor by dominant-negative EGFR-CD533 enhances malignant glioma cell radiosensitivity.

Lammering G, Hewit TH, Holmes M, Valerie K, Hawkins W, Lin PS, Mikkelsen RB, Schmidt-Ullrich RK.

Clin Cancer Res. 2004 Oct 1;10(19):6732-43.

15.

EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines.

Bax DA, Gaspar N, Little SE, Marshall L, Perryman L, Regairaz M, Viana-Pereira M, Vuononvirta R, Sharp SY, Reis-Filho JS, Stávale JN, Al-Sarraj S, Reis RM, Vassal G, Pearson AD, Hargrave D, Ellison DW, Workman P, Jones C.

Clin Cancer Res. 2009 Sep 15;15(18):5753-61. doi: 10.1158/1078-0432.CCR-08-3210. Epub 2009 Sep 8. Erratum in: Clin Cancer Res. 2009 Nov 15;15(22):7110.

16.

The Role of EGFR-Met Interactions in the Pathogenesis of Glioblastoma and Resistance to Treatment.

Guo G, Narayan RN, Horton L, Patel TR, Habib AA.

Curr Cancer Drug Targets. 2017;17(3):297-302. doi: 10.2174/1568009616666161215162515.

PMID:
28004613
17.

Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype.

Choe G, Park JK, Jouben-Steele L, Kremen TJ, Liau LM, Vinters HV, Cloughesy TF, Mischel PS.

Clin Cancer Res. 2002 Sep;8(9):2894-901.

18.
19.

Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis.

Zhu H, Acquaviva J, Ramachandran P, Boskovitz A, Woolfenden S, Pfannl R, Bronson RT, Chen JW, Weissleder R, Housman DE, Charest A.

Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2712-6. doi: 10.1073/pnas.0813314106. Epub 2009 Feb 5.

20.

The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling.

Huang HS, Nagane M, Klingbeil CK, Lin H, Nishikawa R, Ji XD, Huang CM, Gill GN, Wiley HS, Cavenee WK.

J Biol Chem. 1997 Jan 31;272(5):2927-35.

Supplemental Content

Support Center